Lifeward Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Mark Grant
- Full Time Employees
- 80
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 3 Hatnufa Street Yokneam Illit Israel 2069203
- IPO Date
- Sep 12, 2014
- CIK
- 0001607962
- Website
- golifeward.com
- Similar Companies
- Business
- Lifeward Ltd. (Nasdaq: LFWD) designs, develops, and commercializes powered exoskeletons and rehabilitation technologies that enable mobility, gait training, and wellness for individuals with lower limb disabilities, spinal cord injuries, stroke, and neurological conditions. The company offers ReWalk Personal and Rehabilitation Exoskeletons for upright walking, turning, and stair navigation; ReStore soft exo-suit for stroke rehabilitation and functional gait restoration; AlterG Anti-Gravity Treadmill systems for body weight-supported physical therapy, neurological rehabilitation, and athletic training; MyoCycle functional electrical stimulation (FES) cycle devices for therapeutic leg cycling in clinical and home settings; and ReBoot soft exo-suit for post-stroke home and community mobility. Lifeward markets its products directly to hospitals, rehabilitation centers, and individuals, as well as through distributors, serving the United States, Europe, Asia-Pacific, and other international markets. Founded in 2001 and headquartered in Yokneam Illit, Israel, with principal U.S. operations in Marlborough, Massachusetts, the company formerly operated as ReWalk Robotics Ltd. prior to its rebranding to Lifeward Ltd. in September 2024. Recent developments include FDA clearance and U.S. launch of the next-generation ReWalk 7 Personal Exoskeleton in April 2025, achieving record Medicare placements and over 130 qualified U.S. leads; executive appointments of Mark Grant as President and CEO and Almog Adar as CFO in 2025 to drive growth; operational streamlining through closure of two U.S. facilities and manufacturing outsourcing to Cirtronics, targeting $3 million in annual savings and 200 basis point gross margin improvement in 2025 following the 2023 AlterG acquisition integration; and strengthened global manufacturing and partnerships in Israel, Germany, and Massachusetts.
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Lifeward Reports First Quarter 2026 Financial Results
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Lifeward (NASDAQ:LFWD) Trading Up 2.5% – Should You Buy?
Lifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors
Lifeward Announces Reverse Share Split
Lifeward's ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Oramed and Lifeward Announce Strategic Transaction
Lifeward Appoints Bob Marshall as Chairman of the Board